institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

FDA Crackdown on Off-Brand Ozempic Products Set to Take Effect, Threatening Supply and Access for Many

  • The FDA set a May 22, 2025 deadline to stop sales of compounded off-brand semaglutide drugs like Ozempic and Wegovy in the U.S.
  • This action follows prolonged shortages since 2022 and 1,000 reported adverse events linked to unapproved compounded GLP-1 medications lacking FDA approval.
  • Novo Nordisk, the manufacturer of the semaglutide medications approved to treat diabetes and promote weight loss, has increased its legal efforts and marketing campaigns targeting companies that produce unauthorized versions of these drugs.
  • Novo offers new patients a $300 discount on Wegovy, reducing the first month’s cost to $199 from a $1,349 list price, according to Executive VP Dave Moore.
  • The crackdown may reduce cheaper alternatives, likely tightening supply and shifting patients back to high-cost, FDA-approved semaglutide treatments.
Insights by Ground AI
Does this summary seem wrong?

103 Articles

All
Left
10
Center
54
Right
8
KAKE NewsKAKE News
+23 Reposted by 23 other sources
Center

FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs

Key Takeaways

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Grocery Gazette - Latest Grocery Industry News broke the news in on Monday, May 19, 2025.
Sources are mostly out of (0)